🇺🇸 FDA
Patent

US 10940142

Inhibition of crystal growth of roflumilast

granted A61KA61K31/44A61K45/06

Quick answer

US patent 10940142 (Inhibition of crystal growth of roflumilast) held by Arcutis, Inc. expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arcutis, Inc.
Grant date
Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/44, A61K45/06, A61K47/10, A61K9/0014